Aβ12-28P

Aβ12-28P is a synthetic peptide derived from the amyloid-β (Aβ) sequence, specifically residues 12 to 28, with a proline substitution at position 18 that renders it nontoxic and nonfibrillogenic. It is designed to mimic the apoE binding site on full-length Aβ, competitively binding to apolipoprotein E (apoE) with high affinity and thereby preventing the apoE/Aβ interaction. This inhibition enhances the clearance of Aβ and reduces its deposition in the brain, as demonstrated in transgenic mouse models of Alzheimer's disease. Aβ12-28P is blood-brain-barrier-permeable, nonimmunogenic, and shows favorable pharmacokinetic properties due to D-amino acid synthesis and terminal modifications. In preclinical studies, systemic administration of Aβ12-28P significantly reduced amyloid plaque burden and cerebral amyloid angiopathy and prevented memory deficits in animal models of Alzheimer’s disease[1][2][3].